Novacap, a global player in the pharmaceutical and cosmetics industry, announces the acquisition of ID bio, producer of active ingredients of natural origin for cosmetics, as well as H2B, manufacturer of blood fractionation products for in vitro diagnostics .
The Novacap group serves the cosmetics industry through essential ingredients used as preservatives, UV filters, exfoliators and fragrances.
ID bio puts its skills in enzymatic extraction and purification at the service of innovation, in order to strengthen its catalog of active ingredients and botanical extracts. ID bio relies on an ethical sourcing of raw materials, selected in an eco-responsible manner, in order to offer differentiated ingredients with controlled traceability.
The acquisition of ID bio by Novacap is fully in line with the group's growth strategy, which aims to offer its customers a wide range of active and functional ingredients and to expand its portfolio of cosmetic ingredients with products of natural origin.
The company H2B, a sister company of ID bio, will strengthen the positioning of the Novacap Group in the Pharmaceuticals and Healthcare markets.
"The innovation and development capacities of ID bio and H2B enrich the Novacap offer, as well as its ability to meet the requirements of its strategic customers" indicates Pierre Luzeau, President of Novacap.
“The endorsement of Novacap will allow ID bio and H2B to accelerate their development by pooling our market approaches and our recognized expertise. The complementarities between our two groups open up great future prospects for both companies ”declares Jean-Pierre Picot, Founding President of ID bio.
On the strength of this alliance, ID bio and H2B will be able to rely on the industrial and regulatory skills of Novacap, as well as on its large customer portfolio to accelerate their growth.